AbOliGo

AbOliGo is a biotechnology company developing next-generation antibody-oligonucleotide conjugates (AOCs) to unlock the power of multiomic analysis. Its proprietary conjugation platform delivers fast, reproducible, and customizable AOCs for spatial biology, proteomics, and single-cell workflows. By enabling researchers to move seamlessly from antibody to multiomic insight, AbOliGo is redefining what’s possible in biological discovery. Headquartered in Cambridge, UK.

Content by AbOliGo

Colorful abstract molecules on a pink and purple gradient background

| 2 min read

byAbOliGo

AbOliGo closes oversubscribed round to accelerate multiomic research tools and appoints proven life sciences board

New funding will support scaling, team expansion, and the launch of customizable solutions for spatial biology, proteomics, and single-cell analysis.

Industry Perspectives

Page 1 of 1 - 1 Total Items

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Fluorescent-style illustration of spherical embryonic stem cells clustered together against a dark background.

Advancing predictive in vitro models

Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.

Webinars